SCYNEXIS (SCYX) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
19 May, 2026Opening remarks and agenda
The meeting was called to order with board members, executive officers, and the auditor present.
The agenda was limited to one proposal as set forth in the proxy statement.
Specific resolutions to be voted on
The sole proposal was to approve an amendment to the certificate of incorporation to implement a reverse stock split at a ratio between 1-for-5 and 1-for-10, and to decrease the number of authorized shares.
The exact ratio for the reverse split would be determined at the board's discretion.
Corporate governance
Quorum was established with proxies representing 64.9% of outstanding shares.
Scott Sukenick was appointed Inspector of Election.
No additional proposals were filed by shareholders.
Partial view of Summaries dataset, powered by Quartr API
Latest events from SCYNEXIS
- SCY-770 and BARDA-backed SCY-247 advance toward Phase II with runway into 2029.SCYX
3rd Annual Guggenheim Healthcare Innovation Conference - SCY-770 advances toward ADPKD Phase 2 with cash runway into 2029.SCYX
Corporate presentation - SCY-770 enters ADPKD Phase 2 as SCY-247 advances with up to $214M in BARDA support.SCYX
Corporate presentation - A $200 million shelf backs a clinical pipeline facing funding and development risks.SCYX
Registration filing - Clinical progress and BARDA funding support Phase 2 plans, with runway into 2029.SCYX
Q3 2026 - SCY-770 advances toward ADPKD proof-of-concept, with cash runway into 2029.SCYX
Corporate presentation - Phase II trial of SCY-770 for ADPKD to launch by year-end, targeting major unmet need.SCYX
12th Annual Cantor Fitzgerald Global Healthcare Conference - Q2 2026 net income was $7.4M, with strong cash reserves and key clinical milestones ahead.SCYX
Q2 2026 - All six proxy proposals were approved with no shareholder questions submitted.SCYX
AGM 2026